Kevin, Kangjin Jeong
Portland,OR
Summary
Driven by a passion for advancing cancer research, I leveraged molecular biology techniques and in vivo experiments at MD Anderson Cancer Center to uncover critical gene functions and mutations. My expertise in DNA/RNA extraction and innovative cell line management, coupled with a collaborative spirit, has significantly contributed to the development of targeted therapies.
Overview
11
11
years of professional experience
Work History
Assistant Staff Scientist
OHSU Knight Cancer Institute
08.2018 - Current
- Screening for molecular marker (cytokine) from patient blood (plasma) samples by ELISA, and ProQuantum High-Sensitivity Immunoassays (qPCR based).
- Extract DNA/RNA from patient FFPE block and testing for protein-coding related genes. Single cell RNA seq from fresh-collected patient tumor samples.
- Combination drug screening (Breast, Ovarian, Pancreatic cancer cell lines based) for better treatment for patient. PARP and DNA damage relative drugs test. Olaparib (AZD2281) and Saruparib (AZD5305) for PARP inhibitor, Ceralasertib (AZD6738) as ATR inhibitor, Adavosertib (MK-1775) as a Wee1 inhibitor.
- Manage cell lines (240 parental cell lines and 1,350 stable cell lines) at the research laboratory. Lenti-virus transfection made with 2nd and 3rd generations of virus packaging. Making stable cell lines with Lenti-Virus.
Research Scientist
The University of Texas MD Anderson Cancer Center
03.2016 - 07.2018
- I focused on gene functional study. I tested on Normal Human and Mouse cell lines.
- Finding mutation from patients and gene cloning and tested on cell lines. Also, I did several mice work with mutated mouse cell lines. We screened more than 1,000 mutations and reported on Cancer cells.
- Making stable cell lines with Lenti-Virus for normal Human (MCF10A) and normal Mouse (Ba/F3) cell lines.
Postdoctoral Fellow
The University of Texas MD Anderson Cancer Center
05.2013 - 02.2016
- RNA editing research. Focusing on the RNA editing hotspot in miR-200b, a key tumor metastasis suppressor. miR-200b editing level correlates with patient prognosis opposite to the pattern observed for the wild-type miR-200b expression.
- Rational Combination Therapy. Poly (ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells with homologous recombination (HR) deficiency (HRD) caused by mutations in BRCA1, BRCA2, and other pathway members. Testing of BRD4 induced HRD and sensitized cells across multiple tumor lineages to PARPi regardless of BRCA1/2, TP53, RAS, or BRAF mutation status through depletion of the DNA double-stand break resection protein CtIP.
Education
Ph.D. - Molecular & Cellular Biology
Konyang University
Republic Of Korea (South)02.2012
Master of Science - Molecular & Cellular Biology
Konyang University
Republic Of Korea (South)02.2008
Bachelor of Science - Chemistry
Konyang University
Republic Of Korea (South)02.2006
Skills
- Molecular and cellular biology techniques (DNA/RNA extraction, PCRs, ELISA, plate-based assays, WB/IP and data analysis)
- in vitro test and models characterizations (primary cell isolation, 3D models, MPS models, immune-competent in vitro co-culture models)
Timeline
Assistant Staff Scientist
OHSU Knight Cancer Institute
08.2018 - Current
Research Scientist
The University of Texas MD Anderson Cancer Center
03.2016 - 07.2018
Postdoctoral Fellow
The University of Texas MD Anderson Cancer Center
05.2013 - 02.2016
Ph.D. - Molecular & Cellular Biology
Konyang University
Master of Science - Molecular & Cellular Biology
Konyang University
Bachelor of Science - Chemistry
Konyang University
Similar Profiles
Cydney L. BerndtCydney L. Berndt
PAS Resource Specialist at OHSU Knight Cancer InstitutePAS Resource Specialist at OHSU Knight Cancer Institute
Reva HollingsworthReva Hollingsworth
Care Coordinator ll at OHSU Knight Cancer InstituteCare Coordinator ll at OHSU Knight Cancer Institute
Kassidy AkslandKassidy Aksland
Patient Access Resource Specialist at Knight Cancer Institute at OHSUPatient Access Resource Specialist at Knight Cancer Institute at OHSU
COURTNEY PATTERSONCOURTNEY PATTERSON
Asset and Environmental Stewardship (AES) Director at MetroAsset and Environmental Stewardship (AES) Director at Metro
Hanna Valencia MartinezHanna Valencia Martinez
Barista and Cashier at StarbucksBarista and Cashier at Starbucks